rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Annovis Bio, Inc.

ANVS · NYSE

Health CareBiotechnologyNot moving yet

ANVS stood above a rising 150-day average in 11 of the last 52 weekly readings, and has been out of that trend for the last 38 weeks. It is 44.4% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 38
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$6.1M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
58 (+9)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 11 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$2.9MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months9
Sale orders, 12 months0
Buyers · sellers2 · 0
WhoDidSharesTraded
Michael B. HoffmanDirectorbought2,562at $1.7520 May 2026filed 21 May 2026
Michael B. HoffmanDirectorbought18,849at $1.8020 May 2026filed 21 May 2026
Michael B. HoffmanDirectorbought54,933at $1.9020 May 2026filed 21 May 2026
Michael B. HoffmanDirectorbought713,800at $2.102 Apr 2026filed 3 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders58+9 on the quarter
New · exited17 · 8
Reported value$20.0M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Empery Asset Management, LPnew · filed 11 Aug 20262,401,476$4.5M+2,401,476
MARSHALL WACE, LLPadded · filed 13 Aug 20261,842,339$3.4M+654,840+55.1%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20261,647,322$3.1M+774,941+88.8%
TUDOR INVESTMENT CORP ET ALnew · filed 14 Aug 20261,357,134$2.5M+1,357,134
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 20261,002,200$1.9M+654,600+188.3%
TWO SIGMA INVESTMENTS, LPreduced · filed 14 Aug 2026579,571$1.1M-48,088−7.7%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026283,817$528K+36,304+14.7%
BlackRock, Inc.added · filed 7 Aug 2026249,856$465K+110,323+79.1%
CITADEL ADVISORS LLCnew · filed 14 Aug 2026243,682$453K+243,682
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 2026177,530$330K+45,488+34.4%
31 Mar 2023 – 30 Jun 2026
224057Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Michael B. Hoffman Company insiderDirector · last 20 May 20269 · 0
Maria-Luisa Maccecchini Company insiderPresident & CEO · last 28 Oct 20253 · 0
Claudine Bruck Company insiderDirector · last 10 Sep 20252 · 0
Andrew Walsh Company insiderVice President, Finance · last 16 Jun 20250 · 0
Reid McCarthy Company insiderDirector · last 10 Jun 20251 · 0
Mark K. White Company insiderDirector · last 1 Jul 20242 · 0
Henry Hagopian III Company insiderChief Financial Officer · last 20 Nov 20230 · 0
Jeffrey Brian McGroarty Company insiderChief Financial Officer · last 3 Jan 20222 · 0
Robert M. Whelan, Jr. Company insiderDirector · last 1 Jul 20201 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-170%
Share count trendFY 2025 · to 12 Mar 20264.3%
Cash and equivalentsFY 2025 · to 31 Dec 2025$19.5M

Analyst forecasts

No analyst forecasts yet.